Abiopharma

FDA approve MONTELUKAST SODIUM

FDA approve THEOPHYLLINE

FDA approve DOLUTEGRAVIR AND LAMIVUDINE

OncoCyte Corporation (OCX) was removed from the list of traded instruments on NASDAQ exchange

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Oncocyte Corporation - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Oncocyte Corporation - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: Oncocyte Corporation - Common Stock. New value: Oncocyte Corporation - Common Stock.

Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

Biomea Fusion Announces Pricing of Public Offering of Securities

New Form 4 - IRIDEX CORP Filed: 2025-06-17 AccNo: 0000950170-25-087666 Size: 7 KB

New Form 4 - IRIDEX CORP Filed: 2025-06-17 AccNo: 0000950170-25-087664 Size: 5 KB

New Form 4 - IRIDEX CORP Filed: 2025-06-17 AccNo: 0000950170-25-087663 Size: 5 KB

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.